Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Cullinan Oncology (Nasdaq: CGEM) announced on October 3, 2022, that its Board of Directors granted stock options for 242,000 shares of common stock to seven employees. This grant is part of an inducement offer for new hires, aligning with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $12.83, matching the closing stock price on the grant date. Each option has a ten-year term, vesting over four years, with a quarter vesting after one year and the remainder in equal monthly installments over the following 36 months.

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 242,000 shares of its common stock to seven employees outside Cullinan Oncology, Inc.’s 2021 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individuals entering into employment with Cullinan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Seven employees received options to purchase an aggregate of 242,000 shares of Cullinan’s common stock on October 3, 2022 and have an exercise price of $12.83, which is equal to the closing price of Cullinan’s common stock on October 3, 2022. Each option has a ten-year term and vests over four years, with 25 percent of the original number of shares underlying each option vesting on the one-year anniversary of the vesting commencement date and then in equal installments for 36 months thereafter, subject to the employee's continued service with Cullinan through the applicable vesting dates.

About Cullinan Oncology
Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.

Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.

Contacts
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com

FAQ

What stock options were granted by Cullinan Oncology (CGEM) on October 3, 2022?

Cullinan Oncology granted stock options to purchase 242,000 shares of common stock to seven employees.

What is the exercise price for the stock options granted by Cullinan Oncology (CGEM)?

The exercise price for the stock options is $12.83, equal to the closing price on the grant date.

What is the vesting schedule for the stock options granted by Cullinan Oncology (CGEM)?

The options vest over four years, with 25% vesting on the first anniversary and the rest in equal installments over the next 36 months.

Why were the stock options granted to employees at Cullinan Oncology (CGEM)?

The stock options were granted as an inducement for the individuals to enter into employment with Cullinan Oncology.